- First patient delivery of TUDRIQEV achieved in October; over 15 institutions prescribing
- Q2 net loss narrowed to $57.1 million vs. $83.1 million in prior-year period
- Cash and equivalents rose to $307.8M, supported by $141.0M net offering proceeds
?? Positive AI Sentiment (+3.0 / 10)